Vetter Marks the Start of New Clinical Site Con­struction with Ground­breaking Ceremony

Vetter continues to expand in the US

01-Jul-2025
Vetter Pharma International GmbH

Vetter Marks the Start of New Clinical Site Construction with Groundbreaking Ceremony. Participants from left to right: Tom Kikta, Wolfgang Kerkhoff, Gunther Strothe, Dr. Susanne Lemaine, Senator h. c. Udo J. Vetter, Andrew Goczkowski, Thomas Otto, Thomas Rübekeil, Henryk Badack, RT Evans.

Vetter celebrated the start of construction on its new clinical manufacturing site in the Chicago area with an official groundbreaking ceremony. The state-of-the-art facility, which is being built in Des Plaines, Illinois, is expected to be ready for media fill by the end of 2029. This $285 million investment will strengthen Vetter’s position as a leading global partner for aseptic manufacturing in early clinical development.

The new site provides additional capacity for small-batch production of novel active ingredients and includes space for warehouses, laboratories, and administrative offices. The approximately 860,000 square feet site has the capacity to accommodate future expansion, contingent on global demand and additional strategic investments.

"This project marks another milestone in our international growth strategy. It underscores our commitment to quality and innovation, as well as our responsibility to our customers, partners, and patients around the world," Senator h.c. Udo J. Vetter, Chairman of the Advisory Board.

With its new location, Vetter is strengthening its presence in the North American market and supplementing its existing clinical network in Skokie, Illinois and Rankweil, Austria.

Other news from the department manufacturing

Most read news

More news from our other portals

Last viewed contents

A New Era Begins: BioSpring Builds High-Tech Manufacturing Facility for Pharmaceutical Nucleic Acid APIs

A New Era Begins: BioSpring Builds High-Tech Manufacturing Facility for Pharmaceutical Nucleic Acid APIs

GEA invests EUR 80 million in a pharmaceutical technology center for freeze-drying systems in Germany - First product chambers in the “Factory of the Future”

GEA invests EUR 80 million in a pharmaceutical technology center for freeze-drying systems in Germany - First product chambers in the “Factory of the Future”

PL BioScience Announces Major Site Expansion - New 1,200 m² facility in Aachen expands headquarters to support company growth and
scale Human Platelet Lysate production

PL BioScience Announces Major Site Expansion - New 1,200 m² facility in Aachen expands headquarters to support company growth and scale Human Platelet Lysate production

Stora Enso’s billion-euro investment in renewable packaging - Europe's most modern consumer board production line inaugurated in Finland

Stora Enso’s billion-euro investment in renewable packaging - Europe's most modern consumer board production line inaugurated in Finland

NextPharma announces the appointment of Ajeeth Enjeti as CEO to succeed Peter Burema

NextPharma announces the appointment of Ajeeth Enjeti as CEO to succeed Peter Burema

Dr. Roland Durner becomes new CEO of Bioengineering AG

Dr. Roland Durner becomes new CEO of Bioengineering AG

GDCh Award for Biocatalysis for Sebastian Gergel

GDCh Award for Biocatalysis for Sebastian Gergel

Michael Grosse to succeed Joachim Kreuzburg as Chief Executive Officer of Sartorius AG - Grosse to take over as Group CEO on July 1, 2025

Michael Grosse to succeed Joachim Kreuzburg as Chief Executive Officer of Sartorius AG - Grosse to take over as Group CEO on July 1, 2025

WACKER BIOSOLUTIONS under New Leadership - Susanne Leonhartsberger will leave the company at her own request at the end of 2024.

WACKER BIOSOLUTIONS under New Leadership - Susanne Leonhartsberger will leave the company at her own request at the end of 2024.

DMC Biotechnologies announces Dr. Jim Flatt as CEO - DMC seeking to transform how the world makes chemicals

DMC Biotechnologies announces Dr. Jim Flatt as CEO - DMC seeking to transform how the world makes chemicals

Merck: New CEOs for Life Science and Healthcare business sectors and New Chief People Officer - Appointment of three internal senior executives ensures strategic continuity with a new era of leadership

Merck: New CEOs for Life Science and Healthcare business sectors and New Chief People Officer - Appointment of three internal senior executives ensures strategic continuity with a new era of leadership

Joachim Kreuzburg, Former CEO of Sartorius, Joins Cube Biotech’s Board of Directors

Joachim Kreuzburg, Former CEO of Sartorius, Joins Cube Biotech’s Board of Directors